The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis.

doi:10.23736/S1824-4785.21.03343-4

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... - 1 Mar 2023

Domínguez-Ayala Maite, Mínguez-Gabiña Pablo, Paja-Fano Miguel, Bilbao-González Amaia, Expósito-Rodríguez Amaia, Rodeño-Ortiz de Zarate Emilia

Abstract excerpt

BACKGROUND: The BRAF V600E mutation (BRAF mut) in papillary thyroid cancer (PTC) has been associated with poor response to therapy with 131I in patients with metastases but the results in postsurgical treatment are controversial. Our main objective is to investigate the impact of the mutation on the biokinetics of the administered 131I therapy after surgery. METHODS: A prospective study was designed, from July...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Papillary

Share to Iodine Radioisotopes

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Share to Tomography, Emission-Computed, Single-Photon

Share to Tomography, X-Ray Computed

Source

Open in PubMed

Identifiers

PMID: 34477344
DOI: 10.23736/S1824-4785.21.03343-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis.PMID 34477344Read ↗

BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: Should we modify our therapeutic strategy?Semantic proximity Read ↗

Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapySemantic proximity Read ↗

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancerSemantic proximity Read ↗

FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter?Semantic proximity Read ↗

Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.Semantic proximity Read ↗

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases.Semantic proximity Read ↗

Do BRAFV600E mutation and sodium-iodide symporter expression affect the response to radioactive iodine therapy in patients with papillary thyroid carcinoma?Semantic proximity Read ↗

Preliminary Study on The Relationship of BRAF Mutations to The Outcome of The First 131I Radiotherapy and Malignant Biological Characteristics in Papillary Thyroid CarcinomaSemantic proximity Read ↗

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid CancerSemantic proximity Read ↗

BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.Semantic proximity Read ↗

BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposureSemantic proximity Read ↗

Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.